Related Experiment Video

Updated: Jun 3, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Virosome: a novel vector to enable multi-modal strategies for cancer therapy

Yasufumi Kaneda1

  • 1Division of Gene Therapy Science, Osaka University Graduate School of Medicine, Suita, Japan. kaneday@gts.med.osaka-u.ac.jp

Advanced Drug Delivery Reviews
|March 30, 2011
PubMed

Insights

Virosomes, combining viral and non-viral elements, offer a novel approach to cancer therapy. The Hemagglutinating Virus of Japan envelope (HVJ-E) vector shows promise for multi-modal cancer treatment by delivering drugs and genes while activating anti-tumor immunity.

Area of Science:

  • Biotechnology
  • Oncology
  • Virology

Background:

  • Cancer remains a significant health challenge, often requiring multi-modal therapeutic strategies for effective treatment.
  • Current single-modal cancer therapies frequently fall short of achieving complete remission due to treatment resistance.
  • Vector-based gene and drug delivery systems represent a potential revolution in cancer therapy, but face challenges with existing viral and non-viral vectors.

Purpose of the Study:

  • To explore the potential of virosomes as advanced cancer therapeutics.
  • To highlight the advantages of the Hemagglutinating Virus of Japan envelope (HVJ-E) vector in cancer treatment.
  • To discuss the application of virosomes in multi-modal cancer therapy.

Main Methods:

  • Construction of virosomes by integrating viral components with non-viral vectors or using pseudovirions.
  • Utilizing viruses like influenza, HVJ (Sendai virus), and hepatitis B virus in virosome development.
  • Investigating the HVJ-derived vector for efficient delivery of therapeutic agents, including DNA, siRNA, proteins, and anti-cancer drugs.

Main Results:

  • The HVJ-derived vector demonstrates highly efficient delivery capabilities for various therapeutic payloads.
  • The HVJ envelope (HVJ-E) vector possesses intrinsic anti-tumor properties, including immune activation and cancer-selective apoptosis induction.
  • HVJ-E is currently in clinical use for melanoma treatment, showcasing its therapeutic potential.

Conclusions:

  • Virosomes offer a versatile platform for overcoming the limitations of traditional viral and non-viral vectors.
  • The intrinsic anti-tumor activities of HVJ-E, combined with its drug and gene delivery capabilities, position it as a promising candidate for multi-modal cancer therapy.
  • Future applications of virosomes hold significant promise for advancing cancer treatment strategies.

More Related Videos

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

Related Concept Videos

Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...